Chemical Structure (Sorilux 01)
Sorilux Aerosol, Foam
Product Images NDC 51862-376
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sorilux (NDC 51862-376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure A (Sorilux 02)
Figure B (Sorilux 03)
Figure C (Sorilux 04)
Figure D (Sorilux 05)
Figure E (Sorilux 06)
Figure F (Sorilux 07)
Figure G (Sorilux 08)
Principal Display Panel (60 gram Can Carton)
Each can of Sorilux Foam contains 60 grams of a medication called calcipotriene. It is intended for topical use only, and should not be applied to the eyes or used orally or intravaginally. Dosage and prescribing information should be obtained from a patient's physician. The can must be shaken prior to use, and users should avoid puncturing or incinerating the container. The foam is flammable, and users should avoid smoking or exposing it to fire or flame. The product should be kept out of reach of children, and should not be stored above 49°C or in direct sunlight. It contains several ingredients, including calcipotriene, cetyl alcohol, and dibasic sodium phosphate. Adverse reactions should be reported to Mayne Pharma or the FDA.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
